hepatocellular carcinoma

Quiz

HCC Fundamentals

04/26/2022

Test your IO knowledge! Can you correctly answer these 8 questions on the management of hepatocellular carcinoma?

Test your IO knowledge! Can you...

04/26/2022

IO Learning

Clinical Images

Radiation Segmentectomy and Subsegmentectomy of Hepatocellular Carcinoma

10/21/2021

Nariman Nezami , MD;

John T. Moon , MD;

Andrew N. Tran ;

Dr Nezami and colleagues present 2 cases of radiation segmentectomy with yttrium-90 in 2 elderly patients with biopsy-confirmed hepatocellular carcinoma.

Dr Nezami and colleagues present...

10/21/2021

IO Learning

Clinical Images

Transarterial Chemoembolization as a Mechanism to Downstage Patients With Hepatocellular Carcinoma to Transplant Eligibility

10/20/2021

Bryan Wright , BS ;

Robert M. Cannon , MD;

Andrew J. Gunn , MD;

A 63-year-old man diagnosed with HCC was deemed an appropriate liver transplant candidate, but currently outside Milan criteria. He was referred to IR for consideration of TACE as a mechanism to downstage the patient into transplant...

A 63-year-old man diagnosed with...

10/20/2021

IO Learning

NCCN Updates Clinical Practice Guideline for Hepatobiliary Cancers

03/09/2021

Janelle Bradley ;

NCCN released an update to its guideline for hepatobiliary cancers, featuring updates in HCC, gallbladder cancer, intrahepatic cholangiocarcinoma, and biliary tract cancer.

NCCN released an update to its...

03/09/2021

Journal of Clinical Pathways

ENGAGING EXPERTS

High Economic Burden of HCC Treated With Loco-Regional Therapies

01/27/2021

Journal of Clinical Pathways

Videos

Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC

01/26/2021

Journal of Clinical Pathways

News

Using ASCO Value Framework to Compare Treatment Options for HCC

01/21/2021

Journal of Clinical Pathways

Conference Coverage

Lenvatinib Effective for Unresectable HCC in the Real-World Setting

01/16/2021

Journal of Clinical Pathways

Conference Coverage

Atezolizumab Plus Bevacizumab Unlikely to be Cost-Effective Compared With Sorafenib for HCC

01/15/2021

Journal of Clinical Pathways

Pressure Injury Mimicry in an Iso-at-Risk Nursing Home Resident on Regorafenib: Hand-Foot Skin Reaction (HFSR)

A 76-year-old male resident of a skilled nursing facility presented with large deep bilateral heel blisters consistent with stage 2 pressure injuries. His medical problems included hepato...

Deborah Hotep ;

Scott Bolhack , MD, MBA, CMD, CWS, FACP, FAAP;

11/04/2019